Ocunova LLC

Market/Category

  • Diabetic Chronic Dry Eye – Therapeutic

Principal Investigator(s) and Department

Clinical Problem

  • Chronic Dry Eye in the Diabetic patient is prevalent in 20 million people in the US; 50 million worldwide.
  • Most common course of treatment: OTC eye drops that need to be constantly applied or prescription medication that treats inflammation, but not the root cause of dry eyes and corneal sensitivity in the diabetic patient.

Therapeutic Solution

  • Novel (patented) treatment (OCU-001).
  • Significant animal data has proven efficacy and an FDA authorized Phase 1 study that demonstrated treatment was well-tolerated in humans.
  • The OCU-001 formulation treats the source of diabetic dry eye, not just symptoms of inflammation, with a faster onset and reduced side effects to increase patient compliance.

For more information and to contact, please visit Ocunova’s website.